NEW YORK, NY--(Marketwire - Jul 2, 2012) - [ www.ShinesRooms.com ] has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Related Products industry and are offering free analytical research on Perrigo Co. (NASDAQ: [ PRGO ]) and Auxilium Pharmaceuticals Inc. (NASDAQ: [ AUXL ]). Register with us now to have free access to these research reports. Simply click on the link below.

[ http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index ]

Success for drug related products companies, such as Perrigo Co. and Auxilium Pharmaceuticals Inc., seems permanently contingent on their ability to innovate, develop and gain FDA approval. Get your free reports on Perrigo Co. and Auxilium Pharmaceuticals Inc. at [ http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index ]. There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Perrigo Co. and Auxilium Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing. 

[ www.ShinesRooms.com ]

Auxilium recently announced positive top-line results from its phase III studies assessing XIAFLEX^® for the potential treatment of Peyronie's disease. In 2011, sales of Xiaflex represented around 20 percent of the company's sales, so the addition of a new revenue channel from it could boost profitability. Furthermore, Peyronie's disease is a poorly served illness, thus competition is low. Auxilium Pharmaceuticals Inc. report is accessible for free by registering today at

[ http://www.ShinesRooms.com/AuxiliumPharmaceuticalsInc020712.pdf ]

Elsewhere in the industry Perrigo seems focused on expanding its research and development and production of pharmaceuticals. The company lately reported its intention to invest $40 million in operations in Israel over the coming three years. Perrigo has already had success in drug production and sales in the area, as in 2011, sales in Israel grew 20 percent year-over-year to $411 million. Perrigo Co. report is accessible for free by registering today at

[ http://www.ShinesRooms.com/PerrigoCo020712.pdf ]

The two Drug Related Products stocks research reports are available for free by signing up now on the link below.

[ www.ShinesRooms.com ]

About Shinesrooms.com

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link [ http://www.shinesrooms.com/disclaimer.html ].